CSBR - iShares MSCI Brazil ETF USD Acc
| Previous Close | 4.08 |
| Open | 4.08 |
| Bid | 1.76 x 8000 |
| Ask | 199,999.98 x 100 |
| Day's Range | 4.06 - 4.08 |
| 52 Week Range | 2.19 - 4.75 |
| Volume | 206 |
| Avg. Volume | 31,298 |
| Market Cap | 44.663M |
| Beta | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.29 |
| Earnings Date | Nov 27, 2017 - Dec 1, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire•16 days ago
Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House
HACKENSACK, N.J., April 4, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at this year's MicroCap Conference on Tuesday, April 10, 2018 at 9:30am. The MicroCap Conference will take place in New York City at the Essex House on April 9th and 10th.
- ACCESSWIRE•23 days ago
Blog Exposure - Lexicon Announced NDA and MAA Submissions for Sotagliflozin to Treat Adults with Type-1 Diabetes
Stock Monitor: Champions Oncology Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: ...
- PR Newswire•last month
Champions Oncology Reports Quarterly Revenue of $5.1 Million
Company Generates Positive Cash Flow from Operations; Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2018 HACKENSACK, N.J. , March 15, 2018 /PRNewswire/ -- Champions Oncology, ...
- ACCESSWIRE•last month
Champions Oncology, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Champions Oncology, Inc. (NASDAQ: CSBR ) will be discussing their earnings results in their Q3 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern ...
- Simply Wall St.•last month
Does Champions Oncology Inc’s (NASDAQ:CSBR) Past Performance Indicate A Stronger Future?
Assessing Champions Oncology Inc’s (NASDAQ:CSBR) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check toRead More...
- PR Newswire•last month
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 15, 2018
HACKENSACK, N.J., March 7, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2018, on Thursday, March 15, 2018, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 26851, or by accessing the Investor tab of the company's website within 72 hours.
- Simply Wall St.•2 months ago
How Financially Strong Is Champions Oncology Inc (NASDAQ:CSBR)?
Investors are always looking for growth in small-cap stocks like Champions Oncology Inc (NASDAQ:CSBR), with a market cap of US$39.12M. However, an important fact which most ignore is: how financiallyRead More...
- PR Newswire•2 months ago
Champions Oncology to Participate at the 30th Annual ROTH Conference
HACKENSACK, N.J., Feb. 26, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will participate at the 30th Annual Roth Conference and will conduct one-on-one meetings. The conference will be held March 11-13, 2018 at The Ritz Carlton, Laguna Niguel in Orange County, CA and is by invitation only. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.
- PR Newswire•2 months ago
Motivated Patients with ROS1 Cancer Initiate Global Research Study
SAN CARLOS, Calif. and HACKENSACK, N.J., Feb. 21, 2018 /PRNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (CSBR) and the ROS1ders announce the commencement of a global study to gain a deeper understanding of ROS1-positive cancer. The study is developing patient-derived xenografts (PDX) models for ROS1-fusion driven cancers to understand what drives tumor development, therapeutic response and acquired resistance to enable the development of new and more effective therapies against this under-studied molecular subset of cancer.
- Simply Wall St.•2 months ago
February Insights Into Healthcare Stocks: Champions Oncology Inc (NASDAQ:CSBR)
Champions Oncology Inc (NASDAQ:CSBR), a US$38.13M small-cap, is a healthcare company operating in an industry, which continues to endure a more demanding healthcare agenda, and the global need for innovative,Read More...
- Simply Wall St.•4 months ago
Why Champions Oncology Inc’s (NASDAQ:CSBR) CEO Pay Matters To You
Leading Champions Oncology Inc (NASDAQ:CSBR) as the CEO, Ronnie Morris took the company to a valuation of $43.73M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
Capital Cube•4 months agoChampions Oncology, Inc. :CSBR-US: Earnings Analysis: Q2, 2018 By the Numbers : December 19, 2017
Categories: Yahoo FinanceGet free summary analysis Champions Oncology, Inc. reports financial results for the quarter ended October 31, 2017. We analyze the earnings along side the following peers of Champions Oncology, Inc. – Aviragen Therapeutics Inc, Charles River Laboratories International, Inc., Exelixis, Inc., Heska Corporation, NanoString Technologies, Inc., Celldex Therapeutics, Inc., Riot Blockchain Inc and Foundation Medicine, ... Read more (Read more...)
- ACCESSWIRE•4 months ago
Blog Exposure - FDA Granted Tentative Approval for Expanded Label for Egalet’s ARYMO ER Extended-Release Tablets C-II
Stock Monitor: Champions Oncology Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 18, 2017 / Active-Investors issued a free report on Egalet Corp. (NASDAQ: EGLT ), which is readily accessible ...
- PR Newswire•4 months ago
Champions Oncology Reports Record Quarterly Revenue of $5.2 Million
Quarterly operating profit driven by double-digit revenue growth HACKENSACK, N.J. , Dec. 7, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology ...
- Simply Wall St.•4 months ago
Was Champions Oncology Inc’s (CSBR) Earnings Growth Better Than Industry?
Analyzing Champions Oncology Inc’s (NASDAQ:CSBR) track record of past performance is a valuable exercise for investors. It enables us to reflect on whether or not the company has met expectations,Read More...
- PR Newswire•5 months ago
Champions Oncology to Announce Second Quarter Financial Results on Thursday, December 7, 2017
HACKENSACK, N.J., Nov. 28, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2017, on Thursday, December 7, 2017, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 22902, or by accessing the Investor tab of the company's website within 72 hours.
- ACCESSWIRE•5 months ago
Champions Oncology to Present at 10th Annual Main Event on December 5
HACKENSACK, NJ / ACCESSWIRE / November 27, 2017 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use ...
- Simply Wall St.•5 months ago
Champions Oncology Inc (CSBR): Time For A Financial Health Check
Investors are always looking for growth in small-cap stocks like Champions Oncology Inc (NASDAQ:CSBR), with a market cap of USD $41.75M. However, an important fact which most ignore is: howRead More...
- PR Newswire•5 months ago
Champions Oncology to Participate in the Craig-Hallum Alpha Select Investor Conference
HACKENSACK, N.J., Nov. 7, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, will be participating in the 8th Annual Craig-Hallum Alpha Select Conference on November 16th. To schedule a meeting, please contact your Craig-Hallum representative, or Hayden IR. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.
- Simply Wall St.•6 months ago
Champions Oncology Inc (CSBR) And The Healthcare Industry Prospect For 2017
Champions Oncology Inc (NASDAQ:CSBR), a USD$36.03M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...
- PR Newswire•7 months ago
Champions Oncology announces $2 million award from the National Cancer Institute (NCI) to develop and evaluate prostate cancer PDX models
HACKENSACK, N.J., Sept. 26, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the signing of a competitive contract through the government's Small Business Innovation Research (SBIR) program. The contract is in response to Topic 355 – Cell and Animal-Based Models to Advance Cancer Ethnic Health Disparity Research. The project will build and study an ethnically diverse cohort of metastatic prostate patient-derived xenograft (PDX) models. Fully characterized, ethnically diverse prostate PDX models are under-represented among PDX banks, limiting opportunities for pre-clinical and translational oncology studies. Not only is the incidence of prostate cancer higher in African American men than other ethnic groups, the mortality rates from prostate cancer for African American men are higher. A primary goal of this project is to create new tools to better understand the ethnic health disparity in prostate cancer.
Capital Cube•7 months agoChampions Oncology, Inc. :CSBR-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017
Categories: Yahoo FinanceGet free summary analysis Champions Oncology, Inc. reports financial results for the quarter ended July 31, 2017. We analyze the earnings along side the following peers of Champions Oncology, Inc. – Aviragen Therapeutics Inc, Charles River Laboratories International, Inc., Exelixis, Inc., Heska Corporation, NanoString Technologies, Inc., Celldex Therapeutics, Inc. and Foundation Medicine, Inc. (AVIR-US, CRL-US, ... Read more (Read more...)
- PR Newswire•7 months ago
Champions Oncology announces publication highlighting clinical correlation between patient-derived xenograft (PDX) model responses and patient responses to oncology therapies
HACKENSACK, N.J. , Sept. 18, 2017 /PRNewswire/ -- Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the ...
- PR Newswire•7 months ago
Champions Oncology Reports Record Quarterly Revenue of $5 Million
37.1% year-over-year revenue increase HACKENSACK, N.J. , Sept. 14, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services ...
- PR Newswire•7 months ago
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 14, 2017
HACKENSACK, N.J., Sept. 7, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2017, on Thursday, September 14, 2017, after market close. The company will host a conference call to discuss the results that day at 5:00 p.m. EST (2:00 p.m. PST). A replay of the call will be available on the Investor tab of the company's website within 72 hours.
